PBM - Latest News

Psyence Biomedical Ltd. (PBM), operates in Healthcare / Biotechnology, trades on NASDAQ.

Market capitalization stands near $82,162. Trailing twelve-month P/E ratio is 2.43. Beta to the broader market is 1.79.

The article list below shows the most recent PBM headlines from major financial news vendors. For options traders, the most actionable items are earnings releases, analyst rating changes, M&A activity, and regulatory filings - each can drive a meaningful repricing of implied volatility and shift dealer hedging flow. Pair the news context with the implied-volatility skew and gamma exposure views to see whether the options market has already priced in the headline.

Recent PBM Headlines

Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing

globenewswire.com - May 15, 2026

NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Psyence BioMed Ltd. (Nasdaq: PBM) (“Psyence BioMed” or the “Company”), a biopharmaceutical company focused

Pacific Bay Adopts Semi-Annual Reporting

newsfilecorp.com - May 4, 2026

Vancouver, British Columbia--(Newsfile Corp. - May 4, 2026) - Pacific Bay Minerals Ltd.

Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder

globenewswire.com - Apr 23, 2026

Dosing initiates clinical evaluation of NPX-5, a GMP-compliant, nature-derived psilocybin candidate across an expanded Australian site network Dosing

PBM Jumps On Trump Psychedelic Push, Ibogaine Supply Story

feeds.benzinga.com - Apr 20, 2026

Psyence Biomedical (NASDAQ: PBM) stock is surging Monday on a broad psychedelic rally and a company-specific ibogaine supply catalyst.

Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source

globenewswire.com - Apr 20, 2026

NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceu

How News Affects PBM Options Pricing

Headlines and scheduled events drive implied volatility in two distinct ways. Pre-event, IV typically inflates as uncertainty about the outcome rises; this is the implied-volatility expansion that creates the long-vol setup. Post-event, IV typically contracts sharply as uncertainty resolves; this is IV crush, which makes premium-selling structures profitable when they survive the underlying move. The size of the crush depends on how stretched pre-event IV is relative to the realized move. Track PBM's implied vs realized volatility over the news cycle to size pre-event vs post-event positioning. For ticker-level dealer positioning context, the gamma exposure view shows whether dealers are positioned to amplify or dampen post-news moves.

Frequently asked PBM news questions

What is the latest PBM news headline?

The most recent PBM headline (May 15, 2026) is "Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing". The five most recent stories with summaries and publication times are listed above, sourced from major financial news vendors.

How fresh is the PBM news on this page?

News rows refresh roughly every 30 minutes during the trading day. The five most recent headlines are listed in publication-time order. Press releases from the company itself typically appear within minutes of the wire release; third-party reporting may lag by 30-60 minutes depending on the source.

What PBM news moves options pricing?

Three categories move single-name IV most aggressively: scheduled earnings releases (priced into pre-event IV, crushed post-event), unscheduled M&A or strategic announcements (rapid IV expansion, slower decay), and regulatory or legal events (drug-trial readouts, antitrust filings, FDA approvals). Routine news flow (analyst commentary, sector rotation) typically does not move IV meaningfully unless it triggers a cluster of rating changes.

How can I track unusual PBM options activity related to news?

Unusual options activity often precedes news by hours to days; the canonical signals are volume substantially above the trailing average concentrated in a small number of strikes, atypical put/call skew, and aggressive execution (at-the-ask sweeps or block prints). Cross-reference the per-ticker gamma-exposure and volume-history pages with the news flow above to triangulate informed vs uninformed flow.